KB002 / Humanigen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KB002 / Humanigen
ACTRN12606000248561: A phase 1 randomised double blind, placebo-controlled, single dose, dose escalation study of KB002, a chimeric monoclonal antibody which binds to granulocyte macrophage-colony stimulating factor (GM-CSF), in patients with rheumatoid arthritis

Completed
1
32
 
KaloBios Pharmaceuticals, Inc., KaloBios Pharmaceuticals, Inc.
Rheumatoid arthritis
 
 
ACTRN12606000459527: A Phase I Open-Label, Single Dose, Dose Escalation Study of KB002, a Chimeric Monoclonal Antibody Which Binds to GM-CSF (Granulocyte Macrophage Colony Stimulating Factor), in Patients with Chronic Idiopathic Thrombocytopenia Purpura (ITP)

Terminated
1
27
 
KaloBios Pharmaceuticals Inc, KaloBios Pharmaceuticals Inc
Idiopathic Thrombocytopenia Purpura (ITP)
 
 

Download Options